Data gathered: April 15
AI Stock Analysis - DURECT (DRRX)
Analysis generated November 20, 2024. Powered by Chat GPT.
DURECT Corporation is a biopharmaceutical company focused on the development of pharmaceutical systems to improve patient outcomes. The company specializes in creating sustained-release drug delivery technologies and developing a pipeline of novel therapeutic agents for acute and chronic diseases. DURECT's innovative approach aims at providing better therapeutic solutions to address medical needs not fully met by existing treatment options.
Stock Alerts - DURECT (DRRX)
 |
DURECT | April 10 Price is up by 12.1% in the last 24h. |
|
DURECT | April 9 Price is down by -5% in the last 24h. |
|
DURECT | April 8 Price is down by -6.2% in the last 24h. |
|
DURECT | March 26 Price is down by -5.3% in the last 24h. |
Alternative Data for DURECT
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | 59 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 8,327 | Sign up | Sign up | Sign up |
| Twitter Followers | 359 | Sign up | Sign up | Sign up |
| Twitter Mentions | 8 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 91 | Sign up | Sign up | Sign up |
About DURECT
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program.
| Price | $0.73 |
| Target Price | Sign up |
| Volume | 80,520 |
| Market Cap | $23M |
| Year Range | $0.71 - $1.62 |
| Dividend Yield | 0% |
| Analyst Rating | 67% buy |
| Industry | Biotechnology |
In the news
 |
DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.comApril 11 - ETF Daily News |
 |
DURECT (NASDAQ:DRRX) Given Neutral Rating at HC WainwrightMarch 28 - ETF Daily News |
|
DURECT (NASDAQ:DRRX) Now Covered by Analysts at StockNews.comMarch 28 - ETF Daily News |
 |
Here's Why We're A Bit Worried About DURECT's (NASDAQ:DRRX) Cash Burn SituationMarch 27 - Yahoo |
|
Q4 2024 DURECT Corp Earnings CallMarch 26 - Yahoo |
|
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic Focus Amid Financial ChallengesMarch 26 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 1.9M | 3.7M | -1.8M | -4.3M | -3.9M | -0.140 |
| Q2 '24 | 2.2M | 3.3M | -1.2M | -3.7M | -3.3M | -0.120 |
| Q1 '24 | 1.8M | 3.4M | -1.6M | -7.6M | -7.1M | -0.250 |
| Q4 '23 | 2.6M | 3.3M | -740,000 | -1.4M | -820,000 | -0.100 |
| Q3 '23 | 1.7M | 4.1M | -2.4M | -3M | -2.2M | -0.140 |
Insider Transactions View All
| Robertson Judith J. filed to buy 356,132 shares at $0.9. August 22 '22 |
| Robertson Judith J. filed to buy 346,720 shares at $0.8. August 22 '22 |
| Robertson Judith J. filed to buy 267,059 shares at $0.8. August 19 '22 |
| Robertson Judith J. filed to buy 275,189 shares at $0.8. August 19 '22 |
| Maderis Gail J filed to buy 200,000 shares at $0.7. August 12 '22 |
Similar companies
Read more about DURECT (DRRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of DURECT?
The Market Cap of DURECT is $23M.
What is the current stock price of DURECT?
Currently, the price of one share of DURECT stock is $0.73.
How can I analyze the DRRX stock price chart for investment decisions?
The DRRX stock price chart above provides a comprehensive visual representation of DURECT's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling DURECT shares. Our platform offers an up-to-date DRRX stock price chart, along with technical data analysis and alternative data insights.
Does DRRX offer dividends to its shareholders?
As of our latest update, DURECT (DRRX) does not offer dividends to its shareholders. Investors interested in DURECT should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of DURECT?
Some of the similar stocks of DURECT are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.